Summarized by Masters of Longevity from PR Newswire.
Phase III trial results report a dual-biased GLP-1/GIP agonist producing large, sustained weight loss and metabolic improvements with comparatively low GI side effects.
Key Takeaways
- Olatorepatide 15 mg produced mean weight loss of 19.3% at Week 48 versus 2.7% for placebo under the efficacy estimand.
- At Week 48, 71.7% of participants on 15 mg achieved ≥15% weight loss while 3.2% did so on placebo.
- Rates of nausea and vomiting on Olatorepatide were 7.8% and 4.9% respectively, with no treatment-related discontinuations.
